Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
22nd Century, KeyGene launch cannabis technology platform » 10:03
02/10/21
02/10
10:03
02/10/21
10:03
XXII

22nd Century

$3.29 /

+0.065 (+2.02%)

22nd Century Group…

22nd Century Group announced that it has developed and launched a new, cutting-edge technology platform that will enable the Company and its strategic partners to quickly identify and incorporate commercially valuable traits of hemp/cannabis plants to create new, stable hemp/cannabis lines. The platform incorporates a suite of proprietary molecular tools and a large library of genomic markers and gene-trait correlations. The platform was developed in collaboration with researchers at KeyGene, a global leader in plant research involving high-value genetic traits and increased crop yields.

ShowHide Related Items >><<
XXII 22nd Century
$3.29 /

+0.065 (+2.02%)

XXII 22nd Century
$3.29 /

+0.065 (+2.02%)

Over a month ago
Hot Stocks
22nd Century to relocate headquarters to Buffalo's Larkinville District » 10:03
01/28/21
01/28
10:03
01/28/21
10:03
XXII

22nd Century

$2.65 /

+0.12 (+4.74%)

22nd Century Group…

22nd Century Group announced that the Company is moving its corporate headquarters to the up-and-coming Larkinville District in downtown Buffalo. 22nd Century Group's new Buffalo office space is in a restored manufacturing facility located at 500 Seneca Street, joining other multinational technology and professional services companies. The new headquarters will accommodate all of the Company's staff from its current office location in nearby Williamsville and has significant room for expansion. The Company believes that authorization of its MRTP application by the U.S. Food and Drug Administration, along with its expected growth in the hemp/cannabis space and a soon-to-be-announced third franchise, will require an expansion of resources and space. 22nd Century Group will move to its new headquarters in March 2021.

ShowHide Related Items >><<
XXII 22nd Century
$2.65 /

+0.12 (+4.74%)

XXII 22nd Century
$2.65 /

+0.12 (+4.74%)

Hot Stocks
Federal court dismisses class action lawsuit against 22nd Century » 07:31
01/19/21
01/19
07:31
01/19/21
07:31
XXII

22nd Century

$2.77 /

-0.05 (-1.77%)

22nd Century Group…

22nd Century Group announced the dismissal with prejudice of the federal securities class action lawsuit captioned Noto. V. 22nd Century Group, Inc., 19-CV-1285 by a federal district court in the Western District of New York on January 14, 2021. The case was initially filed in the Eastern District of New York, where it was captioned Bull v. 22nd Century Group, Inc. 1:19-CV-00409. In denying the Plaintiffs' request for an opportunity to file another amended Complaint, the Court held that "further amendment would be futile."

ShowHide Related Items >><<
XXII 22nd Century
$2.77 /

-0.05 (-1.77%)

XXII 22nd Century
$2.77 /

-0.05 (-1.77%)

Hot Stocks
22nd Century to expand VLN Tobacco growing program » 12:02
01/11/21
01/11
12:02
01/11/21
12:02
XXII

22nd Century

$2.57 /

-0.06 (-2.28%)

22nd Century Group…

22nd Century Group announced that the Company will significantly expand its growing program for VLN reduced nicotine content tobacco based on the Company's latest sales projections. This new planting for VLN(R) tobacco is in addition to the Company's sizeable inventory of VLN tobacco, which is earmarked for the launch and initial sales of 22nd Century's VLN reduced nicotine content cigarettes. 22nd Century's Modified Risk Tobacco Product application for VLN cigarettes is currently in the final stage of review with the U.S. Food and Drug Administration. Once authorization is granted, 22nd Century will begin marketing its VLN cigarettes, which contain 95% less nicotine than conventional cigarette brands. Having the only combustible cigarette with a modified exposure claim authorized by the FDA could serve as a catalyst for 22nd Century's commercial sales as capturing even a small fraction of U.S. tobacco sales could result in exponential growth in the Company's revenues and market capitalization.

ShowHide Related Items >><<
XXII 22nd Century
$2.57 /

-0.06 (-2.28%)

XXII 22nd Century
$2.57 /

-0.06 (-2.28%)

Hot Stocks
22nd Century receives order for 3.6M SPECTRUM variable nicotine cigarettes » 10:03
12/08/20
12/08
10:03
12/08/20
10:03
XXII

22nd Century

$1.56 /

-0.015 (-0.96%)

22nd Century Group…

22nd Century Group announced that the U.S. Food and Drug Administration in coordination with the National Institute on Drug Abuse and others, has submitted an order to 22nd Century for 3.6 million variable nicotine research cigarettes. The Company's research cigarettes will continue to fuel numerous independent, scientific studies to validate the enormous public health benefits identified by the FDA and others of implementing a national standard requiring all cigarettes to contain minimally or non-addictive levels of nicotine. The selection of SPECTRUM cigarettes for use in ongoing research is not connected to 22nd Century's Modified Risk Tobacco application for the Company's reduced nicotine content VLN cigarettes. 22nd Century believes that authorization of the Company's MRTP application is imminent, and it plans to launch VLN cigarettes within just 90 days of authorization. The company said, "22nd Century continues to maintain a dialogue with the FDA, and the Company believes the agency is in the final stage of review. At this time, the Company has no outstanding requests for information from the FDA, and the Company is confident it has satisfied every FDA requirement for the agency to make a final decision about our application."

ShowHide Related Items >><<
XXII 22nd Century
$1.56 /

-0.015 (-0.96%)

XXII 22nd Century
$1.56 /

-0.015 (-0.96%)

Over a quarter ago
Hot Stocks
22nd Century says 'intensified its proactive efforts' to secure MRTP » 07:07
11/05/20
11/05
07:07
11/05/20
07:07
XXII

22nd Century

$0.73 /

+0.0201 (+2.82%)

"22nd Century…

"22nd Century remains focused on its primary mission of reducing the harm caused by smoking. To this end, in recent weeks the Company has intensified its proactive efforts to secure a Modified Risk Tobacco Product - MRTP - authorization from the U.S. Food and Drug Administration for VLN. With 95% less nicotine than leading brands - or any other cigarette in the U.S. - VLN will make 22nd Century the first, and only company in the world to achieve a MRTP designation for a combustible cigarette. The company has plans in place to commercialize VLN in the U.S. 90 days after receiving MRTP authorization. These plans include a rollout through large, well-recognized retail chains in the U.S. and a marketing campaign to introduce adult smokers to the world's lowest nicotine content cigarette," the company said in its Q3 earnings release.

ShowHide Related Items >><<
XXII 22nd Century
$0.73 /

+0.0201 (+2.82%)

XXII 22nd Century
$0.73 /

+0.0201 (+2.82%)

Earnings
22nd Century reports Q3 EPS (3c), one estimate (4c) » 07:04
11/05/20
11/05
07:04
11/05/20
07:04
XXII

22nd Century

$0.73 /

+0.0201 (+2.82%)

Reports Q3 revenue $7.3M,…

Reports Q3 revenue $7.3M, one estimate $5.5M. "In my first few months as CEO of 22nd Century, I met with scientists, public health officials, national cigarette retailers, farmers, and 22nd Century shareholders. What I heard, from each of these groups, is that 22nd Century's VLN cigarettes have the potential to disrupt and redefine the entire tobacco industry and, in doing so, prevent millions of our nation's youth from becoming addicted to the only legal consumer product that, when used as intended, will kill half of all long-term users. Understanding these facts has helped me to truly appreciate the Company's primary mission of reducing the harm caused by smoking and to reaffirm the Company's strategic priorities," said James Mish, CEO of 22nd Century Group.

ShowHide Related Items >><<
XXII 22nd Century
$0.73 /

+0.0201 (+2.82%)

XXII 22nd Century
$0.73 /

+0.0201 (+2.82%)

Hot Stocks
22nd Century announces grant of new U.S. patent related to nicotine reduction » 13:07
10/14/20
10/14
13:07
10/14/20
13:07
XXII

22nd Century

$0.72 /

-0.0566 (-7.26%)

22nd Century Group…

22nd Century Group announced it was granted a new U.S. patent related to the reduction of nicotine in the tobacco plant. "The new technology provides 22nd Century with a rapid pathway to introduce very low nicotine traits into virtually any variety of tobacco, including bright, burley, oriental, and cigar tobacco varieties," the company said. "We are very pleased to receive this patent which reflects the ingenuity and expertise of our talented scientific team. This new technology allows us to reduce nicotine in any tobacco variety. Importantly, this breakthrough further demonstrates that the FDA's Comprehensive Plan for Tobacco and Nicotine Regulation to limit the nicotine content of all cigarettes sold in the United States is technically feasible and at the same time refutes the claim from 'Big Tobacco' that such low nicotine levels cannot be achieved in multiple tobacco varieties," said James Mish, CEO of 22nd Century Group.

ShowHide Related Items >><<
XXII 22nd Century
$0.72 /

-0.0566 (-7.26%)

XXII 22nd Century
$0.72 /

-0.0566 (-7.26%)

Hot Stocks
22nd Century CEO sends strategy update letter to shareholders » 16:27
09/24/20
09/24
16:27
09/24/20
16:27
XXII

22nd Century

$0.56 /

-0.0215 (-3.68%)

22nd Century provided a…

22nd Century provided a strategy update letter from CEO, James Mish. The letter said: "... On top of everyone's mind is the Company's historic Modified Risk Tobacco Product (MRTP) application with the U.S. Food and Drug Administration (FDA) and the tremendous commercial and public health opportunities it represents. I have spent a great deal of time studying and thinking about our MRTP candidate and am more excited today than when I joined the Company: VLN(R) is a remarkable product and addresses a very large market opportunity. With 95% less nicotine than any leading brand - or any other cigarette in the U.S. - FDA authorization of our VLN(R) MRTP application would give 22nd Century the first and only Modified Risk Tobacco Product designation for a combustible cigarette. VLN(R) would also be the only FDA-authorized MRTP product not developed to create or sustain addiction. After interacting with shareholders, public health officials, and clinicians over the last ten weeks, I have come to recognize how critical VLN(R) and our Company's primary mission really are. Reducing the harm caused by smoking is not only what defines 22nd Century, it is also a mission of which we can all be incredibly proud. It is my pledge to you that we will do everything in our power to bring VLN(R) to market. That is why securing an FDA marketing authorization for our MRTP reduced nicotine content cigarettes is my #1 priority. To this end, we have increased the Company's proactive efforts with the FDA to authorize our MRTP application, as we believe that there is an urgent public health need for a reduced nicotine content combustible alternative like VLN(R). We now believe it is not a matter of if but when our application will be granted, and we believe we are months, not years, away from securing our MRTP designation. I am also proud to report that we have plans in place to commercialize VLN(R) in the U.S. 90 days after we receive our MRTP authorization. These plans include all aspects of supply, manufacturing, sales, and a marketing campaign that has been designed to introduce adult U.S. smokers to the world's lowest nicotine content cigarette... Indeed, having the only combustible cigarette with a modified exposure claim authorized by the FDA, the world's preeminent life-sciences regulatory body, could serve as a catalyst for 22nd Century's commercial sales as even achieving just one-quarter of one percent (0.25%) market share of the U.S. tobacco market could result in revenues that may over time, based on current market multiples, drive the Company's market capitalization more than 5 to 10 times higher than it is today. In addition, FDA authorizing the marketing of 22nd Century's modified risk tobacco products with modified exposure claims would open multiple licensing opportunities for 22nd Century's proprietary reduced nicotine content tobacco to accelerate the commercial and public health potential... 22nd Century's partnership with KeyGene has served as a key competitive advantage for us and we plan to review and refine our focus with KeyGene in the coming months to develop plant lines to serve pharmaceutical and consumer packaged goods, including stable, ultra-high THC lines; rare cannabinoids; and ultra-low terpene modulation to address mal odor and taste in certain consumer and other products. Please also understand that under my watch, 22nd Century will focus the Company's resources only on hemp/cannabis initiatives that have strong consumer or clinical/medical benefits and highly accretive commercial applications. Ultimately, 22nd Century is a plant-based, life science biotechnology company that utilizes both its internal expertise and external strategic resources to create disruptive and proprietary technology with important commercial applications...

ShowHide Related Items >><<
XXII 22nd Century
$0.56 /

-0.0215 (-3.68%)

XXII 22nd Century
$0.56 /

-0.0215 (-3.68%)

Earnings
22nd Century reports Q2 EPS (4c) vs. (6c) a year ago » 07:08
08/06/20
08/06
07:08
08/06/20
07:08
XXII

22nd Century

$0.75 /

-0.0159 (-2.09%)

Reports Q2 revenue $6.4M…

Reports Q2 revenue $6.4M vs. $5.8M a year ago. "Despite the unprecedented challenges brought on by COVID-19, I am pleased to report net sales revenue of $6.4 million for the second quarter of 2020, up 11% from the prior year, continued gross profit margin expansion, and improved operating loss. These results demonstrate our ability to execute on our initiatives to improve our margins and cost structure. Our financial position remains strong and we will continue to operate with strict cost controls, allocate our resources efficiently, and deploy capital where we believe it will give us the greatest return on our investments. With the comment period now closed on our Modified Risk Tobacco Product Application, the team is laser focused on setting the stage for a successful VLN launch upon the authorization of our MRTP Application by the FDA. I am exceedingly proud of the dedication and tremendous progress the team has made so far this year and believe we are well positioned to capitalize on the many opportunities ahead," ," said CEO James Mish.

ShowHide Related Items >><<
XXII 22nd Century
$0.75 /

-0.0159 (-2.09%)

XXII 22nd Century
$0.75 /

-0.0159 (-2.09%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.